DNA vaccination against the parasite enzyme gamma-glutamylcysteine synthetase confers protection against Leishmania donovani infection

Carter, K. C. and Henriquez, F. L. and Campbell, S. A. and Roberts, C. W. and Nok, A. and Mullen, A. B. and McFarlane, E. (2007) DNA vaccination against the parasite enzyme gamma-glutamylcysteine synthetase confers protection against Leishmania donovani infection. Vaccine, 25 (22). pp. 4502-4509. ISSN 1873-2518 (https://doi.org/10.1016/j.vaccine.2007.03.014)

Full text not available in this repository.Request a copy

Abstract

In this study the potential of using Leishmania donovani gamma-glutamylcysteine synthetase (glutamate-cysteine ligase, gamma-GCS) as a rational target for vaccine development was determined. Mice, immunised with plasmid containing the full gene sequence for gamma-GCS (pVAX-gamma GCS) or plasmid alone (pVAX control), were challenged with a high dose of L. donovani amastigotes to give a stringent test of the ability of the vaccine to protect against infection. Vaccination with pVAX-gamma GCS resulted in the production of specific IgG1 and IgG2a antibodies and resulted in significantly lower liver parasite burdens compared to controls. Protection was also associated with a significant increase in cell-mediated immunity, demonstrated as an increase in nitrite production by ConA stimulated splenocytes, an increase in the percentage of splenic CD3(+)CD4(+) cells, and enhanced granuloma maturation, compared to control values. (C) 2007 Elsevier Ltd. All rights reserved.